10.1136/gutjnl-2016-312574 Summary Keywords proton pump inhibitors, digestive diseases, microbiota, intestinal flora, Clostridium difficile , inflammatory bowel disease, short-chain fatty acids Citation Tian L, Huang C, Fu W, Gao L, Mi N, Bai M, Ma H, Zhang C, Lu Y, Zhao J, Zhang X, Jiang N, Lin Y, Yue P, Yuan J and Meng W (2023) Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota
Key Takeaways from Huberman Lab Episodes: Mechanisms of Action : How BPC-157 and similar peptides may assist tissue repair, inflammation reduction, and recovery
The formulation does not contain therapeutic agents and is designed exclusively for reconstituting, diluting, or dissolving compatible compounds prior to research use
These effects (i.e., rapidly reestablished reorganized blood flow) attenuated/eliminated the lesions in the brain (intracerebral and intraventricular hemorrhage), heart (congestion, myocardial infarction, severe arrhythmias), lung (hemorrhage), and congestion in the liver, kidney, and gastrointestinal tract [52,53]
Reputation and Community Presence Before its shutdown, Peptide Sciences had built strong name recognition across peptide communities
It's a modern marvel of biochemistry
